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Polymorphisms in CASP8 at 2q33.1 have been associated with the risk of developing cancer, specifically, the D302H variant
(rs1045485) with breast cancer in the European population and the  652 6N ins/del promoter variant (rs3834129) with multiple
tumours including colorectal cancer (CRC) in the Chinese population. We evaluated the relationship between  652 6N ins/del and
D302H variants and risk of developing CRC in the UK population by genotyping 4016 cases and 3749 controls. Both variants showed
no evidence of an association with risk of developing CRC (P¼0.42 and 0.22, respectively). In contrast, the recently identified CRC
susceptibility allele rs6983267 mapping to 8q24 was significantly associated with disease risk (P¼8.94 10
 8). It is thus very unlikely
that variation in CASP8 defined by  652 6N ins/del or D302H influences the risk of CRC in European populations. The implications
of our findings both in terms of population-specific effects and publication bias are discussed.
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Although inherited susceptibility is responsible for B30% of all
colorectal cancers (CRCs) (Lichtenstein et al, 2000), high-
penetrance, germline mutations in APC, the mismatch repair
(MMR) genes, MUTYH/MYH, SMAD4, ALK3 and STK11/LKB1
account for o5% of cases (Aaltonen et al, 2007). Much of the
remaining variation in genetic risk is likely to be explained by
combinations of more common, lower-penetrance variants.
Although such common alleles may only confer modest
differences in CRC risk through interaction with other common
alleles, some individuals will be placed at a significant risk. Hence,
screening for a battery of such markers potentially has clinical
utility. It is, however, clear that robust validation of novel CRC
predisposition loci is required to avoid spurious testing.
The availability of high-resolution linkage disequilibrium (LD)
maps, and consequently of sets of tagging SNPs that capture much
of the common sequence variation, allows whole-genome-wide
association studies (GWAS) for disease associations to be efficiently
conducted. This approach is attractive as it is unbiased and does not
depend upon prior knowledge of function or presumptive involve-
ment of any gene in disease causation. Furthermore, it minimises
the possibility of failing to identify important variants in hitherto
unstudied genes. Recent GWAS have vindicated the assertion of the
‘common-disease common-variant’ hypothesis providing evidence
for common disease variants for CRC mapping to 8q24 (Haiman
et al, 2007; Tomlinson et al, 2007; Zanke et al, 2007) and SMAD7
(Broderick et al, 2007). The applicability of the GWA strategy,
however, depends heavily on the robustness of tagging, and for
many regions of the genome this may not be optimal. This is a
potentially serious limitation for regions of the genome to which
strong candidate genes map and are not properly tagged.
Caspase 8 (CASP8; MIM 601763) is a key regulator of apoptosis
or programmed cell death, an essential defense mechanism against
hyperproliferation and malignancy. Polymorphic variation in
CASP8 has been reported to influence cancer risk. The variant
D302H (rs1045485) has been associated with risk of breast cancer
in the European population (Cox et al, 2007). Furthermore, the
 652 6N ins/del promoter variant (rs3834129) has been associated
with the risk of developing multiple tumour types, including CRC
in the Chinese population (Sun et al, 2007). It has been asserted
that this specific variant has direct functional effects on cancer risk
on the basis that the deletion destroys a stimulatory protein 1
binding site and decreases CASP8 transcription (Sun et al, 2007).
Moreover, biochemical analyses have shown that T lymphocytes
with the deletion variant have a reduced caspase-8 activity and
activation-induced cell death upon stimulation with cancer cell
antigens (Sun et al, 2007).
To confirm or refute the purported association between  652
6N ins/del and CRC risk and evaluate the relationship between
D302H and CRC risk, we genotyped 4016 cases and 3749 controls
ascertained from the UK population. Risk estimates were
compared with those associated with the 8q24 risk allele
rs6983267 using previously generated data (Tomlinson et al, 2007).
MATERIALS AND METHODS
Subjects
Cases (1930 males, 2086 females; mean age at diagnosis 59.5 years;
s.d.±8.7) were ascertained through the National Study of Colo-
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control individuals (2092 males, 1657 females; mean age 60 years;
s.d.±10.8) were recruited from NSCCG (n¼1843), the Genetic
Lung Cancer Predisposition Study (1999–2004; n¼479) and the
Royal Marsden Hospital Trust/Institute of Cancer Research Family
History and DNA Registry (1999–2004; n¼1427) (Tomlinson
et al, 2007). Cases and controls were British Caucasians, and there
were no obvious differences in the demography of cases and
controls in terms of place of residence within the UK. The study
was conducted with ethics committee approval (MREC/98/2/67;
MREC02/0/97) in accordance with the tenets of the Declaration of
Helsinki, and written informed consent was obtained from all
subjects.
Genotyping
DNA was extracted from samples using conventional methodo-
logies and quantified using PicoGreen (Invitrogen Corp., Carlsbad,
CA, USA). Genotyping of D302H (rs1045485) and  652 6N ins/del
(rs3834129) was conducted by competitive allele-specific PCR
KASPar chemistry (KBiosciences Ltd, Hertfordshire, UK). For
rs1045485, allele-specific primers were: GAAGGTGACCAAGTTCA
TGCTAGATTTGCTCTACTGTGCAGTCATC and GAAGGTCGGAG
TCAACGGATTAGATTTGCTCTACTGTGCAGTCATG; common
primer: GACCACGACCTTTGAAGAGCTTCAT. For rs3834129,
allele-specific primers were: GAAGGTCGGAGTCAACGGATTGCC
ATAGYAATTCTTGCTCTGCCAA and GAAGGTGACCAAGTTCAT
GCTGCCATAGYAATTCTTGCTCTGCCAC; common primer: CAC
TGAGACGTTAAGTAACTTGCCCAA. Genotyping quality control
was tested using duplicate DNA samples within studies and SNP
assays, together with direct sequencing of subsets of samples to
confirm genotyping accuracy. For both SNPs, 99.6% concordant
results were obtained.
Statistical analyses
Statistical analyses were undertaken using STATA Software
(StataCorp LP, College Station, TX, USA). To test for population
stratification, the distribution of genotypes in controls was tested
for a departure from Hardy–Weinberg equilibrium (HWE).
Logistic regression was used to calculate odds ratios (ORs) and
the associated 95% confidence intervals (CIs). Power calculations
were undertaken on the basis of proportions. In all analyses, P-
value of 0.05 was considered significant. Linkage disequilibrium
between genotypes was enumerated using the metric R
2. This was
estimated using Haploview software.
RESULTS AND DISCUSSION
D302H (rs1045485) and  652 6N ins/del (rs3834129) genotypes
were obtained for 96% (3843) and 97% (3879) of CRC cases and
97% (3631) and 98% (3661) of controls, respectively; hence, there
was no evidence of any systematic bias in genotyping. Further-
more, there was no evidence of population stratification, as the
genotype distribution in controls for both variants satisfied HWE
(Table 1). The frequency of the 302H allele (0.132) in our study was
similar to that reported in a other European populations (0.130
(Cox et al, 2007) and 0.125 CEPH (http://www.ncbi.nlm.nih.gov/
projects/SNP/)). In the Chinese population, this SNP has, however,
been documented to be nomomorphic. The frequency of  652 6N
del allele in controls was 0.501, again similar to previously
published data on Europeans. It is, however, markedly different
to that observed in the Chinese population in which the frequency
is B25%.
The frequencies of both variants were not significantly different
in cases and controls (allele test of significance, P¼0.423 and 0.216
respectively; Table 1). There was not strong LD between rs3834129
and rs1045485 (r
2¼0.19). By comparison, the 8q24 variant
rs6983267 displayed a strong association with CRC risk
(P¼8.94 10
 8).
Based on the number of cases and controls analyzed and the
population frequencies of the rare alleles of each polymorphism,
our study has B90% power to demonstrate an OR of 1.2
associated with each variant stipulating a P-value of 0.05. Hence,
while the D302H polymorphism has been robustly shown
to influence breast cancer risk (Frank et al, 2006), our study
indicates that the variant is unlikely to affect risk of CRC and
hence its effect on cancer risks is not generic. Nevertheless, we
cannot exclude the possibility that each variant is associated with
more modest risks of CRC (i.e. o1.2, based upon the upper 95%
CI for ORs).
Table 1 Association between CASP8 variants D302H (rs1045485) and the ±6N promoter variant rs3834129 with colorectal cancer and results are also
shown for the 8q24.21 variant rs6983267
Gene/locus Variant Genotype Cases (%) Controls (%) OR (95% CI)
CASP8 D302H (rs1045485) CC 2890 (75%) 2703 (74%) 1.00 (ref)
CG 894 (23%) 867 (24%) 1.09 (0.75–1.58)
GG 59 (2%) 61 (2%) 1.13 (0.78–1.63)
CG/GG 953 (25%) 928 (26%) 0.96 (0.86–1.07)
Ptrend¼0.67
CASP8  /CTTACT (rs3834129) Ptrend¼0.97
6N ins/ins 995 (26%) 892 (24%) 1.00
6N del/ins 1897 (49%) 1872 (51%) 0.91 (0.81–1.01)
6N del/del 987 (25%) 897 (25%) 0.99 (0.87–1.12)
6Ndel/del
+6N del/ins
2884 (74%) 2769 (76%) 0.93 (0.84–1.04)
Ptrend¼0.83
8q24.21 rs6983267 GG 1102 (31%) 678 (26%) 1.00 (ref)
GT 1824 (51%) 1297 (50%) 0.86 (0.76–0.97)
TT 657 (18%) 604 (23%) 0.67 (0.57–0.77)
GT/TT 2481 (69%) 1901 (73%) 0.80 (0.72–0.90)
Ptrend¼1.13 10
 6
Test of HWE: rs3834129, P¼0.09; rs1045485, P¼0.37; rs6983267, P¼0.74. Crude odds ratios are presented. Ptrend, test of trend across genotypes. Adjustment for age and sex
made no difference to metrics (data not shown).
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breast and CRC in the Chinese population. A recent study of breast
cancer with the Europeans has failed to confirm an association
with breast cancer risk (Frank et al, 2007).
In our study, genotyping was conducted by allele-specific PCR,
generally acknowledged to provide a robust means of assigning
genotypes. In contrast, Sun et al, used PCR-RFLP to determine
genotypes, which through incomplete digestion of PCR product
can lead to misassignment of alleles. This can lead to systematic
basis, especially if cases and controls are not genotyped
simultaneously. Although we cannot entirely exclude the possibi-
lity of such random measurement error as the basis of non-
replication of study findings, it seems unlikely to be a major issue.
While there is evidence that difference in genetic frequencies
across populations of different racial origin is not generally
accompanied by differences in population-specific genetic effects
(Ioannidis et al, 2004), we cannot exclude this possibility.
On the basis of in vitro functional assays, it was asserted that
this variant has direct impact of cancer risk via apoptosis. Allele
frequencies are, however, very different between populations and
the possibility of differential LD in the different populations
remains a basis for non-replication. Alternatively, as the study
purporting that  652 6N ins/del influences CRC was based on a
relatively small sample size to that advocated for GWA analyses,
there remains the distinct possibility of a type 1 error coupled with
publication bias. If additional studies of these variants are
conducted, it opens up the possibility of using meta-analysis to
provide the final step in confirming or refuting an association with
cancer risk.
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